It is known that MiR-146a is a negative regulator of the IFN pathway, and under-expression of MiR-146a conduces to alterations in the type I IFN pathway in lupus patients by targeting the key signaling proteins [54]. Here, IFNA1 is linked to systemic lupus erythematosus.